ANALYSIS OF THE IMPACT OF IMMUNOTHERAPY ON IMMUNE SYSTEM OF THE PATIENTS WITH OVARIAN CANCER (35-40)

DOI:

Дата публикации статьи в журнале: 2018/04/16

Название журнала: Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале, Выпуск: 48, Том: 1, Страницы в выпуске: 35-40

Автор: S. V. Kamyshov
, Republican specialized scientific-practical medical center of oncology and radiology of Ministry of health of the Republic of Uzbekistan ,

Автор: O.M.Akhmedov
, Republican specialized scientific-practical medical center of oncology and radiology of Ministry of health of the Republic of Uzbekistan ,

Автор: M.S.Gildieva
, Republican specialized scientific-practical medical center of oncology and radiology of Ministry of health of the Republic of Uzbekistan ,

Анотация: Тhe aim of the study was to study the effect of immunotherapy on immunopathogenetic elements of the immune system in patients with ovarian cancer with concomitant immunopharmacotherapy. Thus, based on the results obtained, it can be seen that in ovarian cancer, a marked imbalance of the cellular and humoral parts of the immune system is observed. Moreover, the imbalance in the cell elements of immunity is expressed in the suppression of IRI by reducing the number of T-helpers/inducers and increasing T-cytotoxic lymphocytes. CICs of large and small values are also increased, however, the highest increase in CIC was observed in patient groups prior to chemotherapy and immunotherapy, and after the use of chemotherapy without immunotherapy. Increase in T-cytotoxic lymphocytes, which indicates the suppression of T-cell immunity and the presence of cytotoxic action at the cellular level is more typical for terminal stages of cancer. The increase of the main immunoglobulins indicates the presence of a humoral imbalance, and, the increase in the CIC indicates the intoxication of the organism either due to the disintegration of the tumor cells themselves, or against chemotherapy or radiotherapy. An increase in the CIC4% always indicates a progression of the pathological process and is a marker of the progression or deterioration of the clinical course. CIC3% quickly decay in the body, so they have no pathological potential. It has been established positive clinical efficacy of the combination of immunotherapy.

Ключевые слова: ovarian cancer, immunotherapy,extracorporeal immunopharmacotherapy,immunomodulators,lymphocytes,polychemotherapy,

Данные для цитирования: S. V. Kamyshov O.M.Akhmedov M.S.Gildieva. ANALYSIS OF THE IMPACT OF IMMUNOTHERAPY ON IMMUNE SYSTEM OF THE PATIENTS WITH OVARIAN CANCER (35-40) // Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале. Медицинские науки. 2018/04/16; 48(1):35-40.

Скачать в формате PDF

Список литературы: 1. Antoni, P.A. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 // J. Immunother.- 2005. -Vol.28.-P.120-128. 2. Chu C.S., Kim S.H., June C.H. et al. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008;8:243–57 3. Gavalas, N.G. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization // Cancer Res. -2007.-Vol.67(l).-P.354-361. 4. Grivennikov, S.I. Immunity, inflammation and cancer // Cell - 2010.-Vol.l40(6).-P.883-899. 5. Gubser, P. M. et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat. Immunol. 14, 1064–1072 (2013). 6. Kandalaft L.E., Powell D.J. Jr., Singh N., Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol 2011;29:925–33. 7. Liu B., Nash J., Runowicz C. et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010;3:7. 8. Odunsi K., Sabbatini P. Harnessing the immune system for ovarian cancer therapy. Am J Reprod Immunol 2008;59:62–74. 9. Tomsovä, M. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma // Biomed. Biotechnol.- 2010.-2010:435745. 10. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:3360–5. 11. Hung C.F., Wu T.C., Monie A. et al. Antigenspecific immunotherapy of cervical and ovarian cancer. Immunol Rev 2008;222:43–69. 12. Hodi F.S., Mihm M.C., Soiffer R.J. et al. Biologic activity of cytotoxic T lymphocyteassociated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712–7. МЕДИЦИНСКИЕ НАУКИ 13. Sabbatini P., Odunsi K. Immunologic approaches to ovarian cancer treatment. J Clin Oncol 2007;25:2884–93. 14. Sato E., Olson S.H., Ahn J. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538–43. 15. Wu R., Forget M.A., Chacon J. et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012;18(2):160–75.